Virtue® Sirolimus AngioInfusion™ Balloon (SAB)

About Orchestra BioMed

Orchestra BioMed is a publicly traded biomedical innovation company focused on developing high-impact therapeutic solutions for mature medical device markets with significant unmet needs. The company employs a partnership-enabled business model, forging strategic collaborations with leading medical device companies to drive global commercialization. Its two flagship technologies target hypertension and atherosclerotic artery disease, two of the world's leading causes of mortality, with late-stage product candidates designed for rapid adoption and strategic value creation.

About Orchestra BioMed

Orchestra BioMed is a publicly traded biomedical innovation company focused on developing high-impact therapeutic solutions for mature medical device markets with significant unmet needs. The company employs a partnership-enabled business model, forging strategic collaborations with leading medical device companies to drive global commercialization. Its two flagship technologies target hypertension and atherosclerotic artery disease, two of the world's leading causes of mortality, with late-stage product candidates designed for rapid adoption and strategic value creation.

About Orchestra BioMed

Orchestra BioMed is a publicly traded biomedical innovation company focused on developing high-impact therapeutic solutions for mature medical device markets with significant unmet needs. The company employs a partnership-enabled business model, forging strategic collaborations with leading medical device companies to drive global commercialization. Its two flagship technologies target hypertension and atherosclerotic artery disease, two of the world's leading causes of mortality, with late-stage product candidates designed for rapid adoption and strategic value creation.

Therapeutic Areas

Other Coronary In-Stent Restenosis (ISR) Drugs